Last 12 months
Inside the activity.
0 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 1 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 19, 2019 Filed Jun 20, 2019 20:27 UTC |
KELER TIBORExecutive VP & CSO
|
GrantIncentive Stock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0001179110-19-007973 · edgar.xml · derivative · entry 1 KELER TIBOR · CIK 0001429931 · Executive VP & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2029-06-19 F1 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 19, 2019 Filed Jun 20, 2019 20:27 UTC |
MARINO JAMES JDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 4,500 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0001179110-19-007971 · edgar.xml · derivative · entry 1 MARINO JAMES J · CIK 0001198578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 4,500 shares Expires 2029-06-19 F1 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan. Read SEC document |
| June 19, 2019 Filed Jun 20, 2019 20:26 UTC |
Brownlie Keith LDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 4,500 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0001179110-19-007970 · edgar.xml · derivative · entry 1 Brownlie Keith L · CIK 0001518575 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 4,500 shares Expires 2029-06-16 F1 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan. Read SEC document |
| June 19, 2019 Filed Jun 20, 2019 20:26 UTC |
CONRAD HERBERT JDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 4,500 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0001179110-19-007969 · edgar.xml · derivative · entry 1 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 4,500 shares Expires 2029-06-19 F1 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan. Read SEC document |
| June 19, 2019 Filed Jun 20, 2019 20:26 UTC |
PENNER HARRY JRDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 4,500 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0001179110-19-007968 · edgar.xml · derivative · entry 1 PENNER HARRY JR · CIK 0001131148 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 4,500 shares Expires 2029-06-19 F1 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan. Read SEC document |
| June 19, 2019 Filed Jun 20, 2019 20:25 UTC |
Shoos Karen L.Director
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 4,500 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0001179110-19-007967 · edgar.xml · derivative · entry 1 Shoos Karen L. · CIK 0001255681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 4,500 shares Expires 2029-06-19 F1 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan. Read SEC document |
| December 03, 2018 Filed Dec 4, 2018 12:35 UTC |
McMahon Gerald PhDDirector
|
Tax withholdingCommon Stock, par value $0.001 | 2,824 | $0.30 | $843.25 |
DisclosureSEC source: 0001179110-18-013378 · edgar.xml · nonDerivative · entry 1 McMahon Gerald PhD · CIK 0001290747 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,697 F1 · balance_after: On November 28, 2016, in connection with the Reporting Person's employment severance agreement the ("Severance Agreement") with Celldex Therapeutics, Inc. ("Issuer") whereby Issuer agreed to pay Reporting Person 267,356 shares of its common stock, par value $0.001 per share ("Common Stock") less required tax and other withholdings ("Withholdings".) The Reporting Person previously reported ownership of such 267,356 shares on his Form 3 filed with the Securities and Exchange Commission on December 15, 2016. The shares, less Withholdings, are issuable to Reporting Person in equal installments through December 2018. F2 · balance_after: Pursuant to the Severance Agreement, on December 3, 2018, the Issuer issued 5,343 shares of its Common Stock to the Reporting Person. This Form 4 reflects the disposition to the Issuer of 2,824 shares of its Common Stock to satisfy required Withholdings in connection with such issuance of its Common Stock to the Reporting Person. Read SEC document |
| November 01, 2018 Filed Nov 2, 2018 11:50 UTC |
McMahon Gerald PhDDirector
|
Tax withholdingCommon Stock, par value $0.001 | 2,888 | $0.31 | $908.28 |
DisclosureSEC source: 0001179110-18-012450 · edgar.xml · nonDerivative · entry 1 McMahon Gerald PhD · CIK 0001290747 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,521 F1 · balance_after: On November 28, 2016, in connection with the Reporting Person's employment severance agreement (the "Severance Agreement") with Celldex Therapeutics, Inc. ("Issuer") whereby Issuer agreed to pay Reporting Person 267,356 shares of its common stock. par value $0.001 per share ("Common Stock") less required tax and other withholdings (the "Withholdings".) The Reporting Person previously reported ownership of such 267,356 shares on his Form 3 filed with the Securities and Exchange Commission on December 15, 2016. The shares, less Withholdings, are issuable to Reporting Person in equal installments through December 2018. F2 · balance_after: Pursuant to the Severance Agreement, on November 1, 2018, the Issuer issued 5,466 shares of its Common Stock to the Reporting Person. This Form 4 reflects the disposition to the Issuer of 2,888 shares of its Common Stock to satisfy required Withholdings in connection with such issuance of Common Stock to the Reporting Person. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 11:32 UTC |
McMahon Gerald PhDDirector
|
Tax withholdingCommon Stock, par value $0.001 | 2,888 | $0.45 | $1,302.49 |
DisclosureSEC source: 0001179110-18-011797 · edgar.xml · nonDerivative · entry 1 McMahon Gerald PhD · CIK 0001290747 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,409 F1 · balance_after: On November 28, 2016, in connection with the Reporting Person's employment severance agreement with Kolltan Pharmaceuticals, Inc., Reporting Person entered into a severance agreement (the "Severance Agreement") with Celldex Therapeutics, Inc. ("Issuer") whereby Issuer agreed to pay Reporting Person 267,356 shares of its common stock, par value $0.001 per share ("Common Stock") less required tax and other withholdings (the "Withholdings".) The Reporting Person previously reported ownership of such 267,356 shares on his Form 3 filed with the Securities and Exchange Commission on December 15, 2016. The shares, less Withholdings, are issuable to Reporting Person in equal installments through December 2018. F2 · balance_after: Pursuant to the Severance Agreement, on October 1, 2018, the Issuer issued 5,466 shares of its Common Stock to the Reporting Person. This Form 4 reflects the disposition to the Issuer of 2,888 shares of its Common Stock to satisfy required Withholdings in connection with such issuance of Common Stock to the Reporting Person. Read SEC document |
| September 04, 2018 Filed Sep 5, 2018 11:59 UTC |
McMahon Gerald PhDDirector
|
Tax withholdingCommon Stock, par value $0.001 | 2,813 | $0.50 | $1,412.13 |
DisclosureSEC source: 0001182489-18-000319 · edgar.xml · nonDerivative · entry 1 McMahon Gerald PhD · CIK 0001290747 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,297 F1 · balance_after: On November 28, 2016, in connection with the Reporting Person's employment severance agreement with Kolltan Pharmaceuticals, Inc., Reporting Person entered into a severance agreement (the "Severance Agreement") with Celldex Therapeutics, Inc. ("Issuer") whereby Issuer agreed to pay Reporting Person 267,356 shares of its common stock, par value $0.001 per share ("Common Stock") less required tax and other withholdings (the "Withholdings".) The Reporting Person previously reported ownership of such 267,356 shares on his Form 3 filed with the Securities and Exchange Commission on December 15, 2016. The shares, less Withholdings, are issuable to Reporting Person in equal installments through December 2018. F2 · balance_after: Pursuant to the Severance Agreement, On September 4, 2018, the Issuer issued 5,541 shares of its Common Stock to the Reporting Person. This Form 4 reflects the disposition to the Issuer of 2,813 shares of its Common Stock to satisfy required Withholdings in connection with such issuance of Common Stock to the Reporting Person. Read SEC document |
| August 24, 2018 Filed Aug 28, 2018 11:34 UTC |
MARINO JAMES JDirector
|
PurchaseCommon Stock, par value $0.001 per share | 40,000 | $0.48 | $19,200.00 |
DisclosureSEC source: 0001179110-18-010938 · edgar.xml · nonDerivative · entry 1 MARINO JAMES J · CIK 0001198578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,997 Read SEC document |
| August 01, 2018 Filed Aug 2, 2018 11:55 UTC |
McMahon Gerald PhDDirector
|
Tax withholdingCommon Stock, par value $0.001 per share | 2,813 | $0.47 | $1,308.05 |
DisclosureSEC source: 0001179110-18-010087 · edgar.xml · nonDerivative · entry 1 McMahon Gerald PhD · CIK 0001290747 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,110 F1 · balance_after: On November 28, 2016, in connection with the Reporting Person's employment separation agreement with Kolltan Pharmaceuticals, Inc., Reporting Person entered into a severance agreement (the "Severance Agreement") with Celldex Therapeutics, Inc. ("Issuer") whereby Issuer agreed to pay Reporting Person 267,356 shares of its common stock, par value $0.001 per share ("Common Stock") less required tax and other withholdings (the "Withholdings".) The Reporting Person previously reported ownership of such 267,356 shares on his Form 3 filed with the Securities and Exchange Commission on December 15, 2016. The shares, less Withholdings, are issuable to Reporting Person in equal installments through December 2018. F2 · balance_after: Pursuant to the Severance Agreement, on August 1, 2018, the Issuer issued 5,541 shares of its Common Stock to the Reporting Person. This Form 4 reflects the disposition to the Issuer of 2,813 shares of its Common Stock to satisfy required Withholdings in connection with such issuance of Common Stock to the Reporting Person. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 11:43 UTC |
McMahon Gerald PhDDirector
|
Tax withholdingCommon Stock, par value $0.001 per share | 2,813 | $0.50 | $1,416.63 |
DisclosureSEC source: 0001179110-18-009240 · edgar.xml · nonDerivative · entry 1 McMahon Gerald PhD · CIK 0001290747 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,923 F1 · balance_after: On November 28, 2016, in connection with the Reporting Person's employment separation agreement with Kolltan Pharmaceuticals, Inc., Reporting Person entered into a severance agreement (the "Severance Agreement") with Celldex Therapeutics, Inc. ("Issuer") whereby Issuer agreed to pay Reporting Person 267,356 shares of its common stock, par value $0.001 per share ("Common Stock") less required tax and other withholdings (the "Withholdings".) The Reporting Person previously reported ownership of such 267,356 shares on his Form 3 filed with the Securities and Exchange Commission on December 15, 2016. The shares, less Withholdings, are issuable to Reporting Person in equal installments through December 2018. F2 · balance_after: Pursuant to the Severance Agreement, on July 2, 2018, the Issuer issued 5,541 shares of its Common Stock to the Reporting Person. This Form 4 reflects the disposition to the Issuer of 2,813 shares of its Common Stock to satisfy required Withholdings in connection with such issuance of Common Stock to the Reporting Person. Read SEC document |
| June 15, 2018 Filed Jun 18, 2018 12:15 UTC |
KELER TIBORExecutive VP & CSO
|
PurchaseCommon Stock, par value $0.001 per share | 16,500 | $0.59 | $9,782.85 |
DisclosureSEC source: 0001179110-18-008669 · edgar.xml · nonDerivative · entry 1 KELER TIBOR · CIK 0001429931 · Executive VP & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,368 Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 11:57 UTC |
Heath-Chiozzi MargoSVP of Regulatory Affairs
|
GrantIncentive Stock Option (right to buy) · Derivative | 275,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001179110-18-008570 · edgar.xml · derivative · entry 1 Heath-Chiozzi Margo · CIK 0001718112 · SVP of Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2028-06-13 F1 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 13, 2019 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 11:53 UTC |
Martin Samuel BatesSVP and CFO
|
GrantIncentive Stock Option (right to buy) · Derivative | 395,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001179110-18-008569 · edgar.xml · derivative · entry 1 Martin Samuel Bates · CIK 0001709024 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 395,000 Underlying: Common Stock · 395,000 shares Expires 2028-06-13 F1 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 13, 2019 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 11:51 UTC |
Cavanaugh SarahSVP of Corp Affairs & Admin.
|
GrantIncentive Stock Option (right to buy) · Derivative | 275,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001179110-18-008568 · edgar.xml · derivative · entry 1 Cavanaugh Sarah · CIK 0001709113 · SVP of Corp Affairs & Admin. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2028-06-13 F1 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 13, 2019 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 11:48 UTC |
Crowley ElizabethSr. VP &CPDO
|
GrantIncentive Stock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001179110-18-008567 · edgar.xml · derivative · entry 1 Crowley Elizabeth · CIK 0001681854 · Sr. VP &CPDO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2028-06-13 F1 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 13, 2019 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 11:46 UTC |
Wright Richard M.Sr. VP & CCO
|
GrantIncentive Stock Option (right to buy) · Derivative | 275,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001179110-18-008566 · edgar.xml · derivative · entry 1 Wright Richard M. · CIK 0001646423 · Sr. VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2028-06-13 F1 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 13, 2019 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 11:44 UTC |
PEPIN RONALDSr. VP & CBO
|
GrantIncentive Stock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001179110-18-008565 · edgar.xml · derivative · entry 1 PEPIN RONALD · CIK 0001214504 · Sr. VP & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2028-06-13 F1 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 13, 2019 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 11:42 UTC |
KELER TIBORExecutive VP & CSO
|
GrantIncentive Stock Option (right to buy) · Derivative | 390,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001179110-18-008564 · edgar.xml · derivative · entry 1 KELER TIBOR · CIK 0001429931 · Executive VP & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 390,000 Underlying: Common Stock · 390,000 shares Expires 2028-06-13 F1 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 13, 2019 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 11:38 UTC |
Marucci Anthony SDirector · President & CEO
|
GrantIncentive Stock Option (right to buy) · Derivative | 1,075,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001179110-18-008563 · edgar.xml · derivative · entry 1 Marucci Anthony S · CIK 0001429933 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,075,000 Underlying: Common Stock · 1,075,000 shares Expires 2028-06-13 F1 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 13, 2019 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 11:36 UTC |
Brownlie Keith LDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 67,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001179110-18-008562 · edgar.xml · derivative · entry 1 Brownlie Keith L · CIK 0001518575 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,000 Underlying: Common Stock · 67,000 shares Expires 2028-06-13 F1 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 11:34 UTC |
MARINO JAMES JDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 67,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001179110-18-008561 · edgar.xml · derivative · entry 1 MARINO JAMES J · CIK 0001198578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,000 Underlying: Common Stock · 67,000 shares Expires 2028-06-13 F1 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 11:32 UTC |
McMahon Gerald PhDDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 67,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001179110-18-008560 · edgar.xml · derivative · entry 1 McMahon Gerald PhD · CIK 0001290747 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,000 Underlying: Common Stock · 67,000 shares Expires 2028-06-13 F1 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 11:27 UTC |
ELLBERGER LARRYDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 67,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001179110-18-008558 · edgar.xml · derivative · entry 1 ELLBERGER LARRY · CIK 0001219551 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,000 Underlying: Common Stock · 67,000 shares Expires 2028-06-13 F1 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 11:30 UTC |
CONRAD HERBERT JDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 67,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001179110-18-008559 · edgar.xml · derivative · entry 1 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,000 Underlying: Common Stock · 67,000 shares Expires 2028-06-13 F1 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 11:26 UTC |
PENNER HARRY JRDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 67,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001179110-18-008557 · edgar.xml · derivative · entry 1 PENNER HARRY JR · CIK 0001131148 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,000 Underlying: Common Stock · 67,000 shares Expires 2028-06-13 F1 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 11:24 UTC |
Shoos Karen L.Director
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 67,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001179110-18-008556 · edgar.xml · derivative · entry 1 Shoos Karen L. · CIK 0001255681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,000 Underlying: Common Stock · 67,000 shares Expires 2028-06-13 F1 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan. Read SEC document |
| June 01, 2018 Filed Jun 4, 2018 12:15 UTC |
McMahon Gerald PhDDirector
|
Tax withholdingCommon Stock, par value $0.001 per share | 2,813 | $0.58 | $1,632.10 |
DisclosureSEC source: 0001179110-18-007858 · edgar.xml · nonDerivative · entry 1 McMahon Gerald PhD · CIK 0001290747 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,736 F1 · balance_after: On November 28, 2016, in connection with the Reporting Person's employment separation agreement with Kolltan Pharmaceuticals, Inc., Reporting Person entered into a severance agreement (the "Severance Agreement") with Celldex Therapeutics, Inc. ("Issuer") whereby Issuer agreed to pay Reporting Person 267,356 shares of its common stock, par value $0.001 per share ("Common Stock") less required tax and other withholdings (the "Withholdings".) The Reporting Person previously reported ownership of such 267,356 shares on his Form 3 filed with the Securities and Exchange Commission on December 15, 2016. The shares, less Withholdings, are issuable to Reporting Person in equal installments through December 2018. F2 · balance_after: Pursuant to the Severance Agreement, on June 1, 2018, the Issuer issued 5,541 shares of its Common Stock to the Reporting Person. This Form 4 reflects the disposition to the Issuer of 2,813 shares of its Common Stock to satisfy required Withholdings in connection with such issuance of Common Stock to the Reporting Person. Read SEC document |
| May 01, 2018 Filed May 2, 2018 11:16 UTC |
McMahon Gerald PhDDirector
|
Tax withholdingCommon Stock, par value $0.001 per share | 2,813 | $0.74 | $2,081.62 |
DisclosureSEC source: 0001179110-18-006035 · edgar.xml · nonDerivative · entry 1 McMahon Gerald PhD · CIK 0001290747 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,549 F1 · balance_after: On November 28, 2016, in connection with the Reporting Person's employment separation agreement with Kolltan Pharmaceuticals, Inc., Reporting Person entered into a severance agreement (the "Severance Agreement") with Celldex Therapeutics, Inc. ("Issuer") whereby Issuer agreed to pay Reporting Person 267,356 shares of its common stock, par value $0.001 per share ("Common Stock") less required tax and other withholdings (the "Withholdings".) The Reporting Person previously reported ownership of such 267,356 shares on his Form 3 filed with the Securities and Exchange Commission on December 15, 2016. The shares, less Withholdings, are issuable to Reporting Person in equal installments through December 2018. F2 · balance_after: Pursuant to the Severance Agreement, on May 1, 2018, the Issuer issued 5,541 shares of its Common Stock to the Reporting Person. This Form 4 reflects the disposition to the Issuer of 2,813 shares of its Common Stock to satisfy required Withholdings in connection with such issuance of Common Stock to the Reporting Person. Read SEC document |
| April 02, 2018 Filed Apr 3, 2018 11:52 UTC |
McMahon Gerald PhDDirector
|
Tax withholdingCommon Stock, par value $0.001 per share | 3,379 | $2.33 | $7,873.07 |
DisclosureSEC source: 0001179110-18-005108 · edgar.xml · nonDerivative · entry 1 McMahon Gerald PhD · CIK 0001290747 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,362 F1 · balance_after: On November 28, 2016, in connection with the Reporting Person's employment separation agreement with Kolltan Pharmaceuticals, Inc., Reporting Person entered into a severance agreement (the "Severance Agreement") with Celldex Therapeutics, Inc. ("Issuer") whereby Issuer agreed to pay Reporting Person 267,356 shares of its common stock, par value $0.001 per share ("Common Stock") less required tax and other withholdings (the "Withholdings".) The Reporting Person previously reported ownership of such 267,356 shares on his Form 3 filed with the Securities and Exchange Commission on December 15, 2016. The shares, less Withholdings, are issuable to Reporting Person in equal installments through December 2018. F2 · balance_after: Pursuant to the Severance Agreement, on April 2, 2018, the Issuer issued 4,975 shares of its Common Stock to the Reporting Person. This Form 4 reflects the disposition to the Issuer of 3,379 shares of its Common Stock to satisfy required Withholdings in connection with such issuance of Common Stock to the Reporting Person. Read SEC document |
| March 01, 2018 Filed Mar 2, 2018 12:49 UTC |
McMahon Gerald PhDDirector
|
Tax withholdingCommon Stock, par value $0.001 per share | 3,415 | $2.25 | $7,683.75 |
DisclosureSEC source: 0001179110-18-003192 · edgar.xml · nonDerivative · entry 1 McMahon Gerald PhD · CIK 0001290747 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,741 F1 · balance_after: On November 28, 2016, in connection with the Reporting Person's employment separation agreement with Kolltan Pharmaceuticals, Inc., Reporting Person entered into a severance agreement (the "Severance Agreement") with Celldex Therapeutics, Inc. ("Issuer") whereby Issuer agreed to pay Reporting Person 267,356 shares of its common stock, par value $0.001 per share ("Common Stock") less required tax and other withholdings (the "Withholdings".) The Reporting Person previously reported ownership of such 267,356 shares on his Form 3 filed with the Securities and Exchange Commission on December 15, 2016. The shares, less Withholdings, are issuable to Reporting Person in equal monthly installments through December 2018. F2 · balance_after: Pursuant to the Severance Agreement, on March 1, 2018, the Issuer issued 4,939 shares of its Common Stock to the Reporting Person. This Form 4 reflects the disposition to the Issuer of 3,415 shares of its Common Stock to satisfy required Withholdings in connection with such issuance of Common Stock to the Reporting Person. Read SEC document |
| February 01, 2018 Filed Feb 2, 2018 12:35 UTC |
McMahon Gerald PhDDirector
|
Tax withholdingCommon Stock, par value $0.001 per share | 3,415 | $2.76 | $9,425.40 |
DisclosureSEC source: 0001179110-18-001407 · edgar.xml · nonDerivative · entry 1 McMahon Gerald PhD · CIK 0001290747 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,156 F1 · balance_after: On November 28, 2016, in connection with the Reporting Person's employment separation agreement with Kolltan Pharmaceuticals, Inc., Reporting Person entered into a severance agreement (the "Severance Agreement") with Celldex Therapeutics, Inc. ("Issuer") whereby Issuer agreed to pay Reporting Person 267,356 shares of its common stock, par value $0.001 per share ("Common Stock") less required tax and other withholdings (the "Withholdings".) The Reporting Person previously reported ownership of such 267,356 shares on his Form 3 filed with the Securities and Exchange Commission on December 15, 2016. The shares, less Withholdings, are issuable to Reporting Person in equal monthly installments through December 2018. F2 · balance_after: Pursuant to the Severance Agreement, on February 1, 2018, the Issuer issued 4,939 shares of its Common Stock to the Reporting Person. This Form 4 reflects the disposition to the Issuer of 3,415 shares of its Common Stock to satisfy required Withholdings in connection with such issuance of Common Stock to the Reporting Person. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 11:59 UTC |
McMahon Gerald PhDDirector
|
Tax withholdingCommon Stock, par value $0.001 per share | 3,665 | $2.84 | $10,408.60 |
DisclosureSEC source: 0001179110-18-000173 · edgar.xml · nonDerivative · entry 1 McMahon Gerald PhD · CIK 0001290747 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,571 F1 · balance_after: On November 28,2016, in connection with the Reporting Person's employment separation agreement with Kolltan Pharmaceuticals, Inc., Reporting Person entered into a severance agreement (the "Severance Agreement") with Celldex Therapeutics, Inc. ("Issuer") whereby Issuer agreed to pay Reporting Person 267,356 shares of its common stock, par value $0.001 per share ("Common Stock") less required tax and other withholdings (the "Withholdings".) The Reporting Person previously reported ownership of such 267,356 shares on his Form 3 filed with the Securities and Exchange Commission on December 15, 2016. The shares, less Withholdings, are issuable to Reporting Person on equal monthly installments through December 2018. F2 · balance_after: Pursuant to the Severance Agreement, On January 2, 2018, the Issuer issued 4,689 shares of its Common Stock to the Reporting Person. This Form 4 reflects the disposition to the Issuer of 3,665 shares of its Common Stock to satisfy required Withholdings in connection with such issuance of Common Stock to the Reporting Person. Read SEC document |
| December 01, 2017 Filed Dec 1, 2017 13:27 UTC |
McMahon Gerald PhDDirector
|
Tax withholdingCommon Stock, par value $0.001 per share | 3,212 | $3.00 | $9,636.00 |
DisclosureSEC source: 0001179110-17-014753 · edgar.xml · nonDerivative · entry 1 McMahon Gerald PhD · CIK 0001290747 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,236 F1 · balance_after: On November 28, 2016, in connection with the Reporting Person's employment separation agreement with Kolltan Pharmaceuticals, Inc., Reporting Person entered into a severance agreement (the "Severance Agreement") with Celldex Therapeutics, Inc. ("Issuer") whereby Issuer agreed to pay Reporting Person 267,356 shares of its common stock, par value $0.001 per share ("Common Stock") less required tax and other withholdings (the "Withholdings".) The Reporting Person previously reported ownership of such 267,356 shares on his Form 3 filed with the Securities and Exchange Commission on December 15, 2016. The shares, less Withholdings, are issuable to Reporting Person in equal monthly installments through December 2018. F2 · balance_after: Pursuant to the Severance Agreement, on December 1, 2017, the Issuer issued 5,142 shares of its Common Stock to the Reporting Person. This Form 4 reflects the disposition to the Issuer of 3,212 shares of its Common Stock to satisfy required Withholdings in connection with such issuance of Common Stock to the Reporting Person. Read SEC document |
| November 01, 2017 Filed Nov 2, 2017 12:23 UTC |
McMahon Gerald PhDDirector
|
Tax withholdingCommon Stock, par value $0.001 per share | 3,212 | $2.44 | $7,837.28 |
DisclosureSEC source: 0001179110-17-013647 · edgar.xml · nonDerivative · entry 1 McMahon Gerald PhD · CIK 0001290747 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,448 F1 · balance_after: On November 28, 2016, in connection with the Reporting Person's employment separation agreement with Kolltan Pharmaceuticals, Inc., Reporting Person entered into a severance agreement (the "Severance Agreement") with Celldex Therapeutics, Inc. ("Issuer") whereby Issuer agreed to pay Reporting Person 267,356 shares of its common stock, par value $0.001 per share ("Common Stock") less required tax and other withholdings (the "Withholdings".) The Reporting Person previously reported ownership of such 267,356 shares on his Form 3 filed with the Securities and Exchange Commission on December 15, 2016. The shares, less Withholdings, are issuable to Reporting Person in equal monthly installments through December 2018. F2 · balance_after: Pursuant to the Severance Agreement, on November 1, 2017, the Issuer issued 5,142 shares of its Common Stock to the Reporting Person. This Form 4 reflects the disposition to the Issuer of 3,212 shares of its Common Stock to satisfy required Withholdings in connection with such issuance of Common Stock to the Reporting Person. Read SEC document |
| October 03, 2017 Filed Oct 3, 2017 21:27 UTC |
Heath-Chiozzi MargoSVP of Regulatory Affairs
|
GrantIncentive Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $3.01 | $0.00 |
DisclosureSEC source: 0000905718-17-000863 · chiozzi_fm4oct32017.xml · derivative · entry 1 Heath-Chiozzi Margo · CIK 0001718112 · SVP of Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2027-10-03 F1 · security: Represents option granted by Issuer pursuant to its 2008 Stock Option and Incentive Plan. F2 · derivative.exercise_date: 25% vest on October 3, 2018 and the remainder vests quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| October 02, 2017 Filed Oct 2, 2017 20:09 UTC |
McMahon Gerald PhDDirector
|
Tax withholdingCommon Stock, par value $0.001 per share | 3,212 | $2.86 | $9,186.32 |
DisclosureSEC source: 0001179110-17-012836 · edgar.xml · nonDerivative · entry 1 McMahon Gerald PhD · CIK 0001290747 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,660 F1 · balance_after: On November 28, 2016, in connection with the Reporting Person's employment separation agreement with Kolltan Pharmaceuticals, Inc., Reporting Person entered into a severance agreement (the "Severance Agreement")with Celldex Therapeutics, Inc. ("Issuer") whereby Issuer agreed to pay Reporting Person 267,356 shares of its common stock, par value $0.001 per share ("Common Stock") less required tax and other withholdings (the "Withholdings".) The Reporting Person previously reported ownership of such 267,356 shares on his Form 3 filed with the Securities and Exchange Commission on December 15,2016. The shares, less Withholdings, are issuable to Reporting Person in equal monthly installments through December 2018. F2 · balance_after: Pursuant to the Severance Agreement, on October 2, 2017, the Issuer issued 5,142 shares of its Common Stock to the Reporting Person. This Form 4 reflects the disposition to the Issuer of 3,212 shares of its Common Stock to satisfy required Withholdings in connection with such issuance of Common Stock to the Reporting Person. Read SEC document |
| September 01, 2017 Filed Sep 5, 2017 12:17 UTC |
McMahon Gerald PhDDirector
|
Tax withholdingCommon Stock, par value $0.001 per share | 3,212 | $2.46 | $7,901.52 |
DisclosureSEC source: 0001179110-17-011972 · edgar.xml · nonDerivative · entry 1 McMahon Gerald PhD · CIK 0001290747 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,872 F1 · balance_after: On November 28, 2016, in connection with the Reporting Person's employment separation agreement with Kolltan Pharmaceuticals, Inc., Reporting Person entered into a severance agreement (the "Severance Agreement") with Celldex Therapeutics, Inc. ("Issuer") whereby Issuer agreed to pay Reporting Person 267,356 shares of its common stock, par value $0.001 per share ("Common Stock") less required tax and other withholdings (the "Withholdings"). The Reporting Person previously reported ownership of such 267,356 shares on his Form 3 filed with the Securities and Exchange Commission on December 15, 2016. The shares, less Withholdings, are issuable to Reporting Person in equal monthly installments through December 2018. F2 · balance_after: Pursuant to the Severance Agreement, on September 1, 2017, the Issuer issued 5,142 shares of its Common Stock to the Reporting Person. This Form 4 reflects the disposition to the Issuer of 3,212 shares of its Common Stock to satisfy required Withholdings in connection with such issuance of Common Stock to the Reporting Person. Read SEC document |
| August 01, 2017 Filed Aug 1, 2017 20:30 UTC |
McMahon Gerald PhDDirector
|
Tax withholdingCommon Stock, par value $0.001 per share | 2,869 | $2.29 | $6,570.01 |
DisclosureSEC source: 0001179110-17-010880 · edgar.xml · nonDerivative · entry 1 McMahon Gerald PhD · CIK 0001290747 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,084 F1 · balance_after: On November 28, 2016, in connection with the Reporting Person's employment separation agreement with Kolltan Pharmaceuticals, Inc., Reporting Person entered into a severance agreement (the "Severance Agreement") with Celldex Therapeutics, Inc. ("Issuer") whereby Issuer agreed to pay Reporting Person 267,356 shares of its common stock, par value $0.001 per share ("Common Stock") less required tax and other withholdings (the "Withholdings"). The Reporting Person previously reported ownership of such 267,356 shares on his Form 3 filed with the Securities and Exchange Commission on December 15, 2016. The shares, less Withholdings, are issuable to Reporting Person in equal monthly installments through December 2018. F2 · balance_after: Pursuant to the Severance Agreement, on August 1, 2017, the Issuer issued 5,485 shares of its Common Stock to the Reporting Person. This Form 4 reflects the disposition to the Issuer of 2,869 shares of is Common Stock to satisfy required Withholdings in connection with such issuance of Common Stock to the Reporting Person. Read SEC document |
| July 03, 2017 Filed Jul 5, 2017 20:32 UTC |
McMahon Gerald PhDDirector
|
Tax withholdingCommon Stock, par value $.001 per share | 2,869 | $2.47 | $7,086.43 |
DisclosureSEC source: 0001179110-17-009994 · edgar.xml · nonDerivative · entry 1 McMahon Gerald PhD · CIK 0001290747 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,953 F1 · balance_after: On November 28, 2016, in connection with the Reporting Person's employment separation agreement with Kolltan Pharmaceuticals, Inc., Reporting Person entered into a severance agreement (the "Severance Agreement") with Celldex Therapeutics, Inc. ("Issuer") whereby Issuer agreed to pay Reporting Person 267,356 shares of its common stock, par value $0.001 per share ("Common Stock") less required tax and other withholdings (the "Withholdings"). The Reporting Person previously reported ownership of such 267,356 shares on his Form 3 filed with the Securities and Exchange Commission on December 15, 2016. The shares, less Withholdings, are issuable to Reporting Person in equal monthly installments through December 2018. F2 · balance_after: Pursuant to the Severance Agreement, on July 3, 2017, the Issuer issued 5,485 shares of its Common Stock to the Reporting Person. This Form 4 reflects the disposition to the Issuer of 2,869 shares of its Common Stock to satisfy required Withholdings in connection with such issuance of Common Stock to the Reporting Person. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 13:32 UTC |
Brownlie Keith LDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $2.32 | $0.00 |
DisclosureSEC source: 0001179110-17-009169 · edgar.xml · derivative · entry 3 Brownlie Keith L · CIK 0001518575 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2027-06-15 F2 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan. F4 · derivative.exercise_date: 100% of the total amount of shares subject to the Option vests on June 15, 2018. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 13:32 UTC |
Brownlie Keith LDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $2.32 | $0.00 |
DisclosureSEC source: 0001179110-17-009169 · edgar.xml · derivative · entry 2 Brownlie Keith L · CIK 0001518575 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-15 F2 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan. F3 · derivative.exercise_date: Such option vests in three equal annual installments beginning June 15, 2018. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 13:32 UTC |
Brownlie Keith LDirector
|
GrantCommon Stock, par value $0.001 per share | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-17-009169 · edgar.xml · nonDerivative · entry 1 Brownlie Keith L · CIK 0001518575 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · price: On June 15, 2017, the Company awarded 10,000 shares of Company common stock as an annual equity grant in the form of restricted stock awards under the Celldex Therapeutics, Inc. 2008 Stock Option Plan subject to time-based forfeiture restrictions. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 13:32 UTC |
MARINO JAMES JDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $2.32 | $0.00 |
DisclosureSEC source: 0001179110-17-009168 · edgar.xml · derivative · entry 2 MARINO JAMES J · CIK 0001198578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-15 F2 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan. F3 · derivative.exercise_date: Such option vests in three equal annual installments beginning June 15, 2018. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 13:32 UTC |
MARINO JAMES JDirector
|
GrantCommon Stock, par value $0.001 per share | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-17-009168 · edgar.xml · nonDerivative · entry 1 MARINO JAMES J · CIK 0001198578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,997 F1 · price: On June 15, 2017, the Company awarded 10,000 shares of Company common stock as an annual equity grant in the form of restricted stock awards under the Celldex Therapeutics, Inc. 2008 Stock Option Plan subject to time-based forfeiture restrictions. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 13:31 UTC |
McMahon Gerald PhDDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $2.32 | $0.00 |
DisclosureSEC source: 0001179110-17-009167 · edgar.xml · derivative · entry 2 McMahon Gerald PhD · CIK 0001290747 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-15 F2 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan. F3 · derivative.exercise_date: Such option vests in three equal annual installments beginning June 15, 2018. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 13:31 UTC |
McMahon Gerald PhDDirector
|
GrantCommon Stock, par value $0.001 per share | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-17-009167 · edgar.xml · nonDerivative · entry 1 McMahon Gerald PhD · CIK 0001290747 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,822 F1 · price: On June 15, 2017, the Company awarded 10,000 shares of Company common stock as an annual equity grant in the form of restricted stock awards under the Celldex Therapeutics, Inc. 2008 Stock Option Plan subject to time-based forfeiture restrictions. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 13:29 UTC |
CONRAD HERBERT JDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $2.32 | $0.00 |
DisclosureSEC source: 0001179110-17-009166 · edgar.xml · derivative · entry 2 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-15 F2 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan. F3 · derivative.exercise_date: Such option vests in three equal annual installments beginning June 15, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.